ATE132742T1 - Zusammensetzung und verfahren zur behandlung von zystischer fibrose - Google Patents
Zusammensetzung und verfahren zur behandlung von zystischer fibroseInfo
- Publication number
- ATE132742T1 ATE132742T1 AT92912632T AT92912632T ATE132742T1 AT E132742 T1 ATE132742 T1 AT E132742T1 AT 92912632 T AT92912632 T AT 92912632T AT 92912632 T AT92912632 T AT 92912632T AT E132742 T1 ATE132742 T1 AT E132742T1
- Authority
- AT
- Austria
- Prior art keywords
- cystic fibrosis
- macromolecule
- composition
- treating cystic
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74590091A | 1991-08-16 | 1991-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE132742T1 true ATE132742T1 (de) | 1996-01-15 |
Family
ID=24998709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92912632T ATE132742T1 (de) | 1991-08-16 | 1992-05-19 | Zusammensetzung und verfahren zur behandlung von zystischer fibrose |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0599850B1 (de) |
| JP (1) | JPH06510036A (de) |
| AT (1) | ATE132742T1 (de) |
| AU (1) | AU2143992A (de) |
| CA (1) | CA2115364A1 (de) |
| DE (1) | DE69207603T2 (de) |
| WO (1) | WO1993003709A1 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
| US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| WO1994027435A1 (en) | 1993-06-01 | 1994-12-08 | Life Technologies, Inc. | Genetic immunization with cationic lipids |
| US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
| US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
| US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
| US5639661A (en) * | 1994-03-23 | 1997-06-17 | The University Of Iowa Research Foundation | Genes and proteins for treating cystic fibrosis |
| US5863563A (en) * | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
| US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
| US6008202A (en) | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5932241A (en) * | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
| US6258792B1 (en) | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
| WO1997039019A1 (en) | 1996-04-12 | 1997-10-23 | University Of Pittsburgh | Novel cationic cholesteryl derivatives containing cyclic polar groups |
| US6074667A (en) * | 1996-11-20 | 2000-06-13 | Kinnunen; Paavo | Liposomal transfection method |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6251425B1 (en) | 1998-10-02 | 2001-06-26 | Igen, Inc. | Glucoside paucilamellar vesicles |
| PT1129064E (pt) | 1998-11-12 | 2008-01-31 | Invitrogen Corp | Reagentes de transfecção |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| EP1666055A4 (de) * | 2003-07-14 | 2010-02-10 | Viktor Veniaminovich Tets | Verfahren zur behandlung von onkologischen, virulenten und somatischen erkrankungen, verfahren zur kontrolle der behandlungseffizienz, pharmazeutische mittel und zusammensetzung zur durchführung dieser behandlung |
| FR2870741B1 (fr) * | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
| US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
| SG155912A1 (en) | 2005-07-25 | 2009-10-29 | Trubion Pharmaceuticals Inc | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| EP3403667B1 (de) | 2006-09-26 | 2020-07-22 | Infectious Disease Research Institute | Impfstoffzusammensetzung mit einem synthetischen adjuvans |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| EP2095825B8 (de) | 2006-11-28 | 2012-03-28 | CLS Therapeutics Limited | Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| US7964004B2 (en) | 2007-11-16 | 2011-06-21 | Tk Energi A/S | Feeding apparatus for creation of one or more plugs of compressible material for feeding into a gasifier or reactor |
| US9078812B2 (en) | 2007-12-06 | 2015-07-14 | The Bay Zoltan Foundation For Applied Research | Particulate drug carriers as desensitizing agents |
| US10251839B2 (en) | 2008-01-22 | 2019-04-09 | Igi Laboratories, Inc. | Lipid vesicles derived from olive oil fatty acids |
| EP2244694A2 (de) * | 2008-01-29 | 2010-11-03 | Shire Human Genetic Therapies, Inc. | Therapeutische zusammensetzungen mit einem aminhaltigen lipid und einem protein |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| EP2276495B1 (de) | 2008-04-17 | 2018-11-21 | PDS Biotechnology Corporation | Stimulierung einer immunantwort durch enantiomere von kationischen lipiden |
| SI2437753T1 (sl) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo |
| WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
| SI2811981T1 (sl) | 2012-02-07 | 2019-08-30 | Infectious Disease Research Institute | Izboljšanje adjuvantne formulacije, ki obsegajo TLR4 agoniste in postopki za uporabo le-teh |
| EP2822970A1 (de) | 2012-03-08 | 2015-01-14 | Halozyme, Inc. | Bedingt aktive antikörper gegen den epidermalen wachstumsfaktorrezeptor und verfahren zur verwendung davon |
| CA2876155C (en) * | 2012-06-08 | 2022-12-13 | Ethris Gmbh | Pulmonary delivery of mrna to non-lung target cells |
| US10286064B2 (en) | 2012-06-15 | 2019-05-14 | Pds Biotechnology Corporation | Cationic lipid vaccine compositions and methods of use |
| EP4091630A1 (de) | 2012-09-21 | 2022-11-23 | PDS Biotechnology Corporation | Impfstoffe mit r-dotap |
| SG11201503020TA (en) * | 2012-10-29 | 2015-05-28 | Agency Science Tech & Res | A novel reagent for gene-drug therapeutics |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| EP3169310A1 (de) | 2014-07-15 | 2017-05-24 | Life Technologies Corporation | Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen |
| WO2016054005A1 (en) * | 2014-09-30 | 2016-04-07 | The Medical College Of Wisconsin, Inc. | Universal platform for targeting therapies to treat neurological diseases |
| WO2016190780A1 (en) | 2015-05-22 | 2016-12-01 | Dmitry Dmitrievich Genkin | Extracellular dna as a therapeutic target in neurodegeneration |
| EP3352760B1 (de) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3-bindende polypeptide |
| EP3374496A4 (de) | 2015-11-13 | 2019-07-10 | PDS Biotechnology Corporation | Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| CN109310773B (zh) | 2016-05-16 | 2022-04-26 | 传染病研究所 | 含有tlr激动剂的配制品和使用方法 |
| BR112018074352B1 (pt) | 2016-06-01 | 2021-11-30 | Infectious Disease Research Institute | Partículas de nanoalume contendo um agente de dimensionamento |
| EP3493834A1 (de) | 2016-08-07 | 2019-06-12 | Novartis AG | Mrna-vermittelte immunisierungsverfahren |
| US20180153822A1 (en) * | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| EP3638215A4 (de) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Rna-formulierungen |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3461487A1 (de) | 2017-09-29 | 2019-04-03 | Nlife Therapeutics S.L. | Zusammensetzungen und verfahren zur abgabe von mrna an leberzellen |
| WO2019113200A1 (en) | 2017-12-05 | 2019-06-13 | Pds Biotechnology Corporation | Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes |
| KR20200122320A (ko) | 2018-01-16 | 2020-10-27 | 씨엘에스 테라퓨틱스 리미티드 | 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료 |
| CN112839639A (zh) | 2018-08-29 | 2021-05-25 | 川斯勒佰尔公司 | 制备负载mRNA的脂质纳米颗粒的改进方法 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2021127641A1 (en) | 2019-12-20 | 2021-06-24 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| CN115427021A (zh) | 2020-02-25 | 2022-12-02 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0465529B1 (de) * | 1989-03-21 | 1998-04-29 | Vical, Inc. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| ES2210224T3 (es) * | 1989-08-22 | 2004-07-01 | Hsc Research Development Corporation | Gen de la fibrosis quistica. |
-
1992
- 1992-05-19 CA CA002115364A patent/CA2115364A1/en not_active Abandoned
- 1992-05-19 AU AU21439/92A patent/AU2143992A/en not_active Abandoned
- 1992-05-19 WO PCT/US1992/004225 patent/WO1993003709A1/en not_active Ceased
- 1992-05-19 AT AT92912632T patent/ATE132742T1/de not_active IP Right Cessation
- 1992-05-19 EP EP92912632A patent/EP0599850B1/de not_active Expired - Lifetime
- 1992-05-19 DE DE69207603T patent/DE69207603T2/de not_active Expired - Fee Related
- 1992-05-19 JP JP5504268A patent/JPH06510036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0599850B1 (de) | 1996-01-10 |
| DE69207603D1 (de) | 1996-02-22 |
| CA2115364A1 (en) | 1993-03-04 |
| EP0599850A1 (de) | 1994-06-08 |
| JPH06510036A (ja) | 1994-11-10 |
| WO1993003709A1 (en) | 1993-03-04 |
| DE69207603T2 (de) | 1996-09-12 |
| AU2143992A (en) | 1993-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69207603D1 (de) | Zusammensetzung und verfahren zur behandlung von zystischer fibrose | |
| DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
| ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
| DE69830185D1 (de) | Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen | |
| BR9507506A (pt) | Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico | |
| DE69636764D1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
| ATE248586T1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
| DE69822496D1 (de) | Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen | |
| DE3886970D1 (de) | Natürliches oberflächenwirksames Lungenpräparat, Verfahren zu seiner Herstellung und pharmazeutische Zusammensetzungen. | |
| DK0661987T3 (da) | Morphogeninduceret leverregeneration | |
| ATE132040T1 (de) | Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels | |
| SE8000435L (sv) | N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning | |
| DE58901002D1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
| ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| DE69510356D1 (de) | Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie | |
| ATE117898T1 (de) | Verfahren und mittel zur präventiven behandlung von chirurgischen adhäsionen. | |
| ATE187648T1 (de) | Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen | |
| ATE5256T1 (de) | Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel. | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| UA39179C2 (uk) | Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| RU96106437A (ru) | Способ лечения сухой остаточной полости после перенесенного абсцесса легкого | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE106874T1 (de) | Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |